Entity

Time filter

Source Type

Faenza, Italy

Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2009-2.3-1 | Award Amount: 5.41M | Year: 2010

Osteoarthritis (OA) and osteoporosis (OP) are disabling, degenerative bone diseases with significant economic and societal impacts. The incidence of these conditions increases with age but in recent years the number of younger patients has increased, due mainly to factors related to modern life-styles. The efficiency of current pharmacologic and implant-based solutions are limited and often poorly tolerated. OPHIS aims to develop new, engineered biomaterials for the regeneration of both the osteo-chondral region and the vertebral body degenerated by OA and OP. These devices will be based on the unique combination of biological triggers in the form of (i) nanostructured biomaterials able to mimic the extracellular matrices of either bone or cartilage (ii) chemical and biochemical cues able to direct, control and preserve the phenotypes of the relevant cells in their respective histological compartments. OPHIS will explore the frontiers of knowledge of the effect of nano-structures on tissue regeneration and lead to the de-novo design of active structures able to trigger this process. User friendly and highly performing tissue substitutes will be developed as both acellular and cellular matrices for the regeneration of specific anatomical regions compromised by OA and OP. Focus will also be given to the study of the interactions occurring at nano-scale level between the implanted materials and the natural tissues. This information will complement the body of data obtained through clinically reflective in vitro and in vivo models. Dissemination will be integrated step-wise with the strategy for intellectual property protection and exploitation.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2007-2.3-1 | Award Amount: 11.09M | Year: 2008

The main driving idea of the project is the creation of conceptually new type of scaffolds able to be manipulated in situ by means of magnetic forces. This approach is expected to generate scaffolds with such characteristics as multiple use and possibly multipurpose delivery in order to repair large bone defects and ostheocondral lesions in the articular surface of the skeletal system. The major limitations of the scaffolds for bone and cartilage regeneration nowadays available in the market are related to the difficulties in controlling cell differentiation and angiogenesis processes and to obtain stable scaffold implantation in the pathological site. . . Several attempts have been performed over the last years in order to provide scaffolds for tissue engineering, but nowadays there is no way to grant that tissue regeneration take place in the pathological site. The provision in vivo of the scaffold with staminal cells or /and growth factors in order to drive the tissue differentiation process and parallel angiogenesis represents nowadays one of most challenging requests [Ref. Nanomedicine roadmap]. The Consortium aims to elaborate, investigate and fabricate new kind of scaffolds magnetic scaffolds (MagS) - characterized by strongly enhanced control and efficiency of the tissue regeneration and angiogenic processes. The magnetic moment of the scaffolds enables them with a fascinating possibility of being continuously controlled and reloaded from external supervising center with all needed scaffold materials and various active factors (AF). Such a magnetic scaffold can be imagined as a fixed station that offers a long-living assistance to the tissue engineering, providing thus a unique possibility to adjust the scaffold activity to the personal needs of the patient.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-2 | Award Amount: 8.33M | Year: 2011

Despite significant achievements in the field of regenerative medicine and the enormous potential for engineered tissue products, significant hurdles have prevented cellular therapies from gaining wide-spread clinical adoption. Manufacturing related issues have been proposed as key challenges to be addressed for the translation of regenerative therapies to the clinic and the successful commercialization of engineered products. Similar to other biotechnology sectors (e.g., vaccines or recombinant protein production), bioreactor systems could play a central role in establishing engineered tissues in the clinic. In fact, by automating and streamlining manufacturing processes, they would allow to improve product reproducibility, safety, standardization and possibly reach cost-effectiveness. This project aims at the development, pre-clinical and clinical testing of a sensor-based bioreactor system for the production of functional, autologous engineered grafts with reproducible properties. The bioreactor-based manufacturing paradigm will be addressed in the specific context of cartilage repair. Innovative features of the proposed tissue engineering strategy will include: (i) an automated and controlled production system, (ii) bioreactor conforming to regulatory guidelines, (iii) simplified, streamlined, and scalable tissue engineering process, (iv) on-line monitoring of culture/quality parameters, and (v) data management systems for traceability. To achieve these goals, BIO-COMET brings together internationally renowned leaders in the field of regenerative medicine, from academic, clinical and industrial research institutions. Successful implementation of the project will be instrumental to extend use of bioreactor-based platforms beyond cartilage tissue engineering, with the ultimate goal to facilitate broad utilization and commercialization of cell-based grafts as therapeutic solutions.


Trademark
Fin Ceramica Faenza S.P.A. | Date: 2010-01-05

Chemical used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manure; fire extinguishing compositions; tempering and soldering chemicals; chemical substances for preserving foodstuffs; tanning agents for use in the manufacture of leather; tanning chemicals; adhesives used in industry. Pharmaceutical and veterinary preparations for the treatment of articular joint and bone defects in humans and animals; sanitary preparations for medical purposes; dietetic foods adapted for medical use; foodstuffs for babies; medical plasters, medical dressings; material for stopping teeth, dental wax; all purpose disinfectants; preparations for destroying vermin; fungicides, herbicides; composite based on calcium phosphates and animal or human materials, namely, collagen demineralized bone matrix; natural bone materials derived from animals or human sources, namely, alumina and hydroxyapatite for use in surgical procedures; implantable medical devices containing materials of human origin such as pastes of calcium phosphate and demineralized bone matrix, namely, knee prosthesis. Surgical, medical, dental, orthopedic and veterinary apparatus and instruments, namely, orthopedic joint implants, artificial limbs, eyes and teeth, orthopedic articles, namely, articular joint prosthesis, suture materials, dental prostheses, bone substitutes for surgical use, namely, cervical spacers for intersomatic grafts; artificial bone parts to be implanted in natural material for filing bony tissue; long-term implantable medical devices, namely, prosthetic knees, shoulders, ankles, hips; medical devices of calcium phosphate and reabsorbable polymers, namely, hydroxyapatite bone and cartilage substitutes; prosthetics devices, namely, knee prosthesis; implantable devices for prosthetic joints made of metal, polymeric and inert or active ceramic materials in the nature of calcium phosphate, namely, resurfacing knee prosthesis, unicompartmental knee prostheses, total knee prostheses; implantable medical devices for the regeneration of chondral and osteochondral defects, namely, artificial cartilage and bone for implantation; implantable medical devices for the regeneration of bone defects, namely, bone substitute; biocompatible artificial materials for implantable surgical devices, namely, knee prosthesis.


Trademark
Fin Ceramica Faenza S.P.A. | Date: 2008-02-19

Chemical used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering chemicals; chemical substances for preserving foodstuffs; tanning agents for use in the manufacture of leather; tanning chemicals; adhesives used in industry. Pharmaceutical and veterinary preparations for the treatment of articular joint and bone defects in humans and animals; sanitary preparations for medical purposes; dietetic foods adapted for medical use; foodstuffs for babies; medical plasters, medical dressings; material for stopping teeth, dental wax; all purpose disinfectants; preparations for destroying vermin; fungicides, herbicides; composite based on calcium phosphates and animal or human materials, namely, collagen demineralized bone matrix; natural bone materials derived from animals or human sources, namely, alumina and hydroxyapatite for use in surgical procedures; implantable medical devices containing materials of human origin such as pastes of calcium phosphate and demineralized bone matrix, namely, knee prosthesis. Surgical, medical, dental, orthopedic and veterinary apparatus and instruments, namely, orthopedic joint implants, artificial limbs, eyes and teeth, orthopedic articles, namely, articular joint prosthesis, suture materials, dental prostheses, bone substitutes for surgical use, namely, cervical spacers for intersomatic grafts; artificial bone parts to be implanted in natural material for filing bony tissue; long-term implantable medical devices, namely, prosthetic knees, shoulders, ankles, hips; medical devices of calcium phosphate and reabsorbable polymers, namely, hydroxyapatite bone and cartilage substitutes; prosthetics devices, namely, knee prosthesis; implantable devices for prosthetic joints made of metal, polymeric and inert or active ceramic materials in the nature of calcium phosphate, namely, resurfacing knee prosthesis, unicompartmental knee prostheses, total knee prostheses; implantable medical devices for the regeneration of chondral and osteochondral defects, namely, artificial cartilage and bone for implantation; implantable medical devices for the regeneration of bone defects, namely, bone substitute; biocompatible artificial materials for implantable surgical devices, namely, knee prosthesis.

Discover hidden collaborations